Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.
Zoledronate is a Nitrogen containing bisphosphonate (NBP) used in many conditions like osteoporosis, Paget's disease and hypercalcemia of malignancy. Unlike oral bisphosphonates, Zoledronate is not seen to be associated with gastroesophageal side effects but the drug is not free of certain rare but life threatening adverse effects like hypocalcemia and renal deterioration. Majority of cases of hypocalcemia with Zoledronate are seen in patients with underlying malignancy and are asymptomatic. Here we present a case of severe symptomatic hypocalcemia along with hypophosphatemia following zoledronate administration in an elderly male with a history of osteoporotic fracture.
Upinder
U
Kaur
Sankha Shubhra
SS
Chakrabarti
Division of Geriatrics, Department of General Medicine Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, UP, India. iac2k10@gmail.com.
Indrajeet Singh
IS
Gambhir
D000368:Aged; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced* / Q000175:diagnosis; D017674:Hypophosphatemia / Q000139:chemically induced* / Q000175:diagnosis; D007093:Imidazoles / Q000009:adverse effects*; D008297:Male; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid